- Record: found
- Abstract: not found
- Article: not found
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
X. Pivot ,
J. Gligorov ,
V. Müller ,
G. Curigliano ,
A. Knoop ,
S. Verma ,
V. Jenkins ,
N. Scotto ,
S. Osborne ,
L. Fallowfield ,
Lesley Fallowfield ,
Valerie Jenkins ,
Justine Kilkerr ,
Carolyn Langridge ,
Kathryn Monson ,
Erik Hugger Jakobsen ,
Mette Holck Nielsen ,
Soeren Linnet ,
Ann Knoop ,
Xavier Pivot ,
Herve Bonnefoi ,
Mireille Mousseau ,
Laurent Zelek ,
Hugues Bourgeois ,
Claudia Plesse Lefeuvre ,
Thomas Bachelot ,
Thierry Petit ,
Etienne Brain ,
Christelle Levy ,
Joseph Gligorov ,
Doris Augustin ,
Heiko Graf ,
Georg Heinrich ,
Hendrik Kroening ,
Sherko Kuemmel ,
Volkmar Müller ,
Friedrich Overkamp ,
Tjoung-Won Park-Simon ,
Marcus Schmidt ,
Lidia Perlova-Griff ,
Christopher Wolf ,
Marco Colleoni ,
Alberto Ballestrero ,
Antonio Bernardo ,
Angela Stefania Ribecco ,
Luca Gianni ,
Giuseppe Curigliano ,
Elżbieta Brewczynska ,
Jacek Jassem ,
Vadim Shirinkin ,
Alexey Manikhas ,
Victoria Dvornichenko ,
Mikhail Lichinitser ,
Vladimir Semiglazov ,
Guzel Mukhametshina ,
Irina Bulavina ,
Enrique Espinosa Arranz ,
Francisco Carabantes Ocon ,
Guillermo López Vivanco ,
Javier Salvador Bofill ,
Ignacio Porras Quintela ,
Alfonso Sanchez Muñoz ,
Yolanda Fernández Pérez ,
Javier Cassinello Espinosa ,
José Valero Alvarez ,
Rodrigo Lastra del Prado ,
LuisLa Cruz De Merino ,
José Manuel Pérez García ,
Santos Enrech Frances ,
Per Edlund ,
Bengt Norberg ,
Anna-Karin Wennstig ,
Pehr Lind ,
Nik Hauser ,
Christoph Tausch ,
Celalettin Camci ,
Fikret Arpaci ,
Huseyin Abali ,
Ruchan Uslu ,
Saad Tahir ,
Duncan Wheatley ,
Stephen Chan ,
Peter Barrett-Lee ,
Karen McAdam ,
Richard Simcock ,
Russell Burcombe ,
Robert El-Maraghi ,
Nadia Califaretti ,
Silvana Spadafora ,
Sandeep Sehdev ,
Amer Sami ,
Sunil Verma
October 2014
October 2014
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous (s.c.)
trastuzumab, delivered via single-use injection device (SID), over the intravenous
(i.v.) formulation (Cohort 1 of the PrefHer study: NCT01401166). Here, we report patient
preference, healthcare professional satisfaction, and safety data pooled from Cohort
1 and also Cohort 2, where s.c. trastuzumab was delivered via hand-held syringe.